Archived Monthly Oncology Tumor Boards: Uveal Melanoma: Treatment of Metastatic Disease

The management of metastatic uveal melanoma still presents a major clinical challenge among physicians. Since the most common site of metastasis is the liver, and efficient management of liver metastases can improve disease outcome, it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel. Uveal melanoma can also metastasize to sites other than the liver, and while existing treatment options are limited, recent exciting clinical trial results offer hope for these patients.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify disease and patient characteristics indicative of poor prognoses for metastatic uveal melanoma.
  • Outline treatment options for patients with metastatic uveal melanoma.
  • Summarize existing challenges to the treatment of patients with metastatic uveal melanoma.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Exact Sciences
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis

This activity is supported by independent educational grants from:

  • Merck & Co., Inc.
  • Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

This educational activity is supported by medical education grants from:

  • Exelixis, Inc.
  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 

Miguel A. Materin, MD
Duke Cancer Institute

Harriet Kluger, MD
Yale Cancer Center/Smilow Cancer Hospital

Mario Sznol, MD
Yale Cancer Center/Smilow Cancer Hospital


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Miguel A. Materin, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Castle Biosciences, Inc.: Consulting Fee
IDEAYA Biosciences: Consulting Fee

Harriet Kluger, MD
Apexigen: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Calithera Biosciences, Inc.: Consulting Fee
ChemoCentryx, Inc.: Consulting Fee
Clinigen: Consulting Fee
GigaGen, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support 
Pliant Therapeutics: Consulting Fee
Signatera: Consulting Fee 

Mario Sznol, MD
Adagene: Consulting Fee 
Adaptimmune Therapeutics plc: Consulting Fee 
Adaptive Biotechnologies: Equity Interest/Stock Options
Actym Therapeutics, Inc.: Equity Interest/Stock Options
Agenus Inc.: Consulting Fee  
Alligator Bioscience: Consulting Fee 
Amphivena Therapeutics: Equity Interest/Stock Options
Apexigen: Consulting Fee  
Asher Biotherapeutics, Inc.: Equity Interest/Stock Options
AstraZeneca Pharmaceuticals LP: Consulting Fee 
Biond Biologics: Consulting Fee 
BioNTech SE: Consulting Fee 
Boston Pharmaceuticals: Consulting Fee 
Bristol-Myers Squibb Company: Consulting Fee 
Dragonfly Therapeutics, Inc.: Consulting Fee 
EvolveImmune Therapeutics: Equity Interest/Stock Options
Evaxion Biotech AS: Consulting Fee 
Genentech – Roche: Consulting Fee 
Genocea Biosciences: Consulting Fee 
Gilead Sciences, Inc.: Consulting Fee 
GlaxoSmithKline: Equity Interest/Stock Options
Idera Pharmaceuticals, Inc.: Consulting Fee 
Immunocore Ltd.: Consulting Fee 
Incyte Corporation: Consulting Fee 
Innate Pharma S.A.: Consulting Fee  
Intensity Therapeutics: Equity Interest/Stock Options
ITeos Therapeutics: Consulting Fee 
Jazz Pharmaceuticals Inc.: Consulting Fee 
Johnson & Johnson: Equity Interest/Stock Options
Kadmon – Sanofi: Consulting Fee 
Kanaph Therapeutics: Consulting Fee 
Laboratoires Pierre Fabre: Consulting Fee 
Molecular Partners AG: Consulting Fee 
NextCure, Inc.: Equity Interest/Stock Options 
Normunity Inc.: Consulting Fee; Equity Interest/Stock Options
Numab Therapeutics AG: Consulting Fee 
Ocellaris – Lilly: Consulting Fee 
OncoHost: Equity Interest/Stock Options
OncoSec Medical: Consulting Fee 
Ontario Institute for Cancer Research: Consulting Fee  
Pfizer Inc.: Consulting Fee 
PIO Therapeutics: Consulting Fee 
Pliant Therapeutics: Consulting Fee 
Regeneron Pharmaceuticals, Inc.: Consulting Fee 
Repertoire Immune Medicines: Equity Interest/Stock Options
Rootpath, Inc.: Equity Interest/Stock Options
Rubius Therapeutics, Inc: Consulting Fee 
Sapience Therapeutics, Inc.: Consulting Fee 
Servier Pharmaceuticals: Consulting Fee 
Simcha Therapeutics: Consulting Fee 
STCube Inc.: Consulting Fee 
Targovax: Consulting Fee 
Tessa Therapeutics Ltd.: Consulting Fee 
Verastem Oncology: Consulting Fee 
Xilio Therapeutics: Consulting Fee

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-032-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 17, 2024. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00054479; Approval #: 230000928

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing